| Impact of mycophenolate mofetil (MMF)‐related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients JC Tierce, J Porterfield‐Baxa, AA Petrilla, A Kilburg, RM Ferguson Clinical transplantation 19 (6), 779-784, 2005 | 126 | 2005 |
| Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications EG Hagenmeyer, B Häussler, E Hempel, G Grannas, Z Kaló, A Kilburg, ... Transplantation 77 (10), 1545-1550, 2004 | 79 | 2004 |
| Using GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLI L Kleinman, A Kilburg, G Machnicki, R Faull, R Walker, R Prasad, ... Quality of life research 15, 1223-1232, 2006 | 57 | 2006 |
| Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study ME Backhouse, M Wonder, E Hornby, A Kilburg, M Drummond, FK Mayer Value in Health 14 (4), 608-615, 2011 | 44 | 2011 |
| Using multicriteria decision analysis during drug development to predict reimbursement decisions P Williams, J Mauskopf, J Lebiecki, A Kilburg Journal of Market Access & Health Policy 2 (1), 25270, 2014 | 17 | 2014 |
| The cost of mycophenolate mofetil-related (MMF) gastrointestinal adverse events and impact of MMF dose-reductions/discontinuations on acute rejection in transplanted patients RM Ferguson, J Porterfield-Baxa, JC Tierce, AA Petrilla, A Kilburg European Society for Organ Transplantation, Venice, Italy, 20-24, 2003 | 5 | 2003 |
| Die adjuvante Arzneimitteltherapie der Alkoholkrankheit mit Acamprosat R Rychlik, B Paschen, D Kirchhoff, D Daniel, T Pfeil, A Kilburg DMW-Deutsche Medizinische Wochenschrift 126 (33), 899-904, 2001 | 5 | 2001 |
| Adjuvant drug treatment of alcoholism with acamprosate: between sectoral budgets and disease management R Rychlik, B Paschen, D Kirchhoff, D Daniel, T Pfeil, A Kilburg Deutsche Medizinische Wochenschrift (1946) 126 (33), 899-904, 2001 | 5 | 2001 |
| Kostenanalyse eines Diagnostik-Screenings zur Differenzierung von Typ-1-und Typ-2-Diabetikern im Alter von 30 bis 45 Jahren: Gesundheitsökonomische Modellrechnung A Kilburg, Y Bruchhausen, J Thomas, R Rychlik DMW-Deutsche Medizinische Wochenschrift 124 (50), 1510-1517, 1999 | 5 | 1999 |
| The burden of illness of diabetes mellitus type 2 in Germany—a pilot study M Tepe, A Kilburg, D Daniel, D Kirchhoff, R Rychlik Value in Health 4 (2), 111-111, 2001 | 4 | 2001 |
| The basics of health economics: An example from dermatology R Rychlik, A Kilburg Dermatology and Psychosomatics/Dermatologie und Psychosomatik 1 (3), 105-109, 2000 | 4 | 2000 |
| Die frühzeitige Behandlung des Diabetes mellitus Typ 2 mit oralen Antidiabetika A Kilburg, D Daniel, R Rychlik Gesundheitsökonomie & Qualitätsmanagement 6 (02), 59-63, 2001 | 2 | 2001 |
| German recommendations on health economic evaluation studies. Revised version of the hannover consensus: Revidierte Fassung des Hannoveraner Konsens K Bestehorn, M Biller, JG Brecht, J Clouth, FU Fricke, G Glaeske, ... Medizinische Klinik 95, 52-55, 2000 | 2 | 2000 |
| PDB6: THE FINANCIAL EFFECTS OF INTERFACE AGREEMENTS FOR DIABETES MELLITUS: SOCIOECONOMIC RELEVANCE OF INTENSIVE CONTROLLED INSULIN THERAPY WITH INSULIN LISPRO COMPARED TO … A Kilburg, J Clouth, D Daniel, D Kirchhoff, R Rychlik Value in Health 5 (3), 339-340, 2000 | 2 | 2000 |
| PHP118 Estimating the Probability of a Recommendation for Reimbursement for a New Drug in the UK Using an MCDA Approach P Williams, JA Mauskopf, A Kilburg, J Lebiecki Value in Health 15 (7), A309-A310, 2012 | 1 | 2012 |
| PHP125 An Early Assessment of the German Federal Joint Commission Resolutions of Additional Clinical Benefit D McBride, A Kilburg, J Mauskopf Value in Health 15 (7), A311, 2012 | 1 | 2012 |
| Healthcare Reforms in Germany: Managed Care, An Opportunity? R Rychlik, K Güntert-Gömann, A Kilburg, JB Frazier Disease Management and Health Outcomes 8, 305-312, 2000 | 1 | 2000 |
| PHP112 Estimating the Probability of a Favorable Assessment of Clinical Benefits for a New Drug in Germany Using an MCDA Approach P Williams, J Mauskopf, A Kilburg, J Lebiecki Value in Health 15 (7), A308, 2012 | | 2012 |
| PGI5 GASTROINTESTINAL MEDICATION USE AND COSTS IN HEART TRANSPLANT RECIPIENTS RECEIVING MYCOPHENOLATE MOFETIL AP Legorreta, AS Gilmore, J Marehbian, C Naujoks, A Kilburg Value in Health 9 (6), A242-A243, 2006 | | 2006 |
| DETERMINING THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE IN PATIENT REPORTED SYMPTOM SEVERITY AND GI-SPECIFIC HRQOL SCORES FOR RENAL TRANSPLANT PATIENTS WITH GI COMPLAINTS. A Kilburg, D Revicki, A Gnanasakthy, L Kleinman, L Chan Transplantation 82 (1), 517, 2006 | | 2006 |
